IngentaConnect Drug Delivery to the Brain - Realization by Novel Drug Carriers

Authors: Rainer H. Müller; Cornelia M. Keck

Source: Journal of Nanoscience and Nanotechnology, Volume 4, Number 5, October 2004 , pp. 471-483(13)

Publisher: American Scientific Publishers

Abstract:

Delivery of drugs to the brain is still a major challenge. Successful delivery across the bloodbrain barrier has only been achieved in some cases, e.g., using pro-drugs. The review describes the delivery to the brain using nanoparticulate drug carriers in combination with the novel targeting principle of "differential protein adsorption" (PathFinder^® technology). The PathFinder technology exploits proteins in the blood which adsorb onto the surface of intravenously injected carriers for targeting. Apolipoprotein E is the targeting moiety for the delivery of particles to the endothelials of the blood-brain barrier. To reach therapeutic drug level in the brain, nanoparticulate drug carriers with sufficiently high loading capacity are reviewed, including drug nanocrystals (nanosuspensions), lipid drug conjugate (LDC) nanoparticles and lipid nanoparticles (solid lipid nanoparticles–SLN, nanostructured lipid carriers–NLC). The features are described, including regulatory aspects and large scale production.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$413.00 plus tax Refund Policy

Drug Delivery to the Brain – Realization by Novel Drug Carriers